Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-MIP-1095 in mCRPC
NCT03030885Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mip-1095 i-131 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2017; status: completed.
02
Drugs
mip-1095 i-131
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03030885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030885.